Medical

Marinomed Biotech has announced that a Phase 3 trial of Budesolv budesonide nasal spray has met its primary endpoint. Without providing any specific data, the company said that, "The top line results are now available and show that Budesolv achieves at least the same effect as the product which is currently on the market, with a significantly lower dose." According to … [Read more...] about Marinomed Biotech says Phase 3 trial of Budesolv nasal spray met primary endpoint

Novus Therapeutics said that two Phase 1 trials of its OP0201 intranasal MDI, which is in development for otitis media, both met their primary endpoints. In one of the studies, healthy adults received either a single 20 mg dose of OP0201 or placebo and were then exposed to pressure changes in a pressure chamber. In the other, adults with acute otitis media received 20 … [Read more...] about Phase 1 trials of intranasal MDI for otitis media meet primary endpoints

The UK's National Institute for Health Care and Excellence (NICE) has issued a new "patient decision aid" that emphasizes that a metered dose inhaler "contains propellant, so it has a higher carbon footprint than a DPI." In a statement, NICE explains, "Where several inhalers could be viable options, patients can opt for the more environmentally friendly option, which … [Read more...] about NICE suggests patients use “greener” DPIs instead of MDIs

VistaGen Therapeutics has presented new data from a Phase 3 study of PH94B nasal spray for the treatment of social anxiety disorder (SAD) at the 2019 Anxiety and Depression Association of America (ADAA) Annual Conference. VistaGen acquired the rights to PH948B from Pherin Pharmaceuticals in September 2018. According to Vistagen, patients who received PH94B … [Read more...] about VistaGen presents new data from Phase 3 study of PH94B nasal spray for social anxiety disorder

Savara has announced the initiation of the Phase 2a ENCORE study of its Molgradex inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of nontuberculous mycobacterial (NTM) lung infection in cystic fibrosis patients. The company is also developing Molgradex for the treatment of NTM lung infections in non-CF patients and … [Read more...] about Savara begins Phase 2a trial of Molgradex for the treatment of NTM lung infection in CF patients

Biohaven Pharmaceutical said that it has initiated a Phase 2/3 study of its BHV-3500 intranasal calcitonin gene-related peptide (CGRP) receptor antagonist for the treatment of migraine. The company announced positive results from a Phase 1 study of BHV-3500 in February 2019. The trial will compare 5, 10, and 20 mg doses of BHV-3500 delivered by Aptar Pharma's Unit … [Read more...] about Biohaven initiates Phase 2/3 study of BHV-3500 intranasal therapy for migraine

The Alzheimer’s Drug Discovery Foundation has awarded a grant worth approximately $1.2 million to a team led by Hiroaki Sato and Thomas Schricker at the Research Institute of the McGill University Health Centre (RI-MUHC) for research into the effectiveness of intranasal insulin for delirium and cognitive dysfunction experienced by patients following surgery. Sato … [Read more...] about McGill University team gets funding for project evaluating intranasal insulin for postoperative cognitive impairment

Auris Medical has announced the initiation of a Phase 1b proof-of-concept study of its AM-201 intranasal betahistine, which the company is developing for the prevention of weight gain and sleepiness in patients taking olanzapine. The 4-week dose escalation study is expected to compare 5 different doses of AM-201 to placebo in 50 healthy volunteers who will also … [Read more...] about Phase 1b trial of Auris Medical’s intranasal betahistine gets underway